Through the ADVOCATE program, ARPA-H is developing FDA-approved agentic AI systems for cardiovascular care to provide 24/7 specialized assistance to heart patients.[1][2][6] The program is funding the development of a patient AI agent focused on heart failure and myocardial infarction that will connect to electronic health records, wearable devices, schedule appointments, adjust medications, provide diet and exercise advice, and conduct clinical assessments over the phone.[1][2][4] The second system is a surveillance agent to monitor the safety and effectiveness of these AIs.[1][2][4] Cardiovascular disease causes approximately 200,000 deaths in the US each year.[1] ARPA-H will select teams of innovators by June 2026, followed by a year of competitive bidding, and the entire program, including development, deployment, and FDA review, will take about 39 months.[1][3] AI agents will be deployed in healthcare systems after two years to assess clinical and operational impact.[1] The program works with the FDA to determine the evidence for authorization and supports the US AI Action Plan.[2][6]